Differences in oestrogen and progesterone receptors, HER-2 and p53 expression and proliferation in ductal breast cancers in relation to histopathological grade

Folia Morphologica

Volumn 64, Issue 1, 2005, Pages 9-15

  Zasławski, Ryszard ^a   Surowiak, Paweł ^b,c   Paluchowski, Piotr ^d   Dziegiel, Piotr ^b   Maciejczyk, Adam ^c   Pudełko, Marek ^c   Wojnar, Andrzej ^c   Zabel, Maciej ^b,e  

^a Voivodship Hospital   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

^d Klinikum Pinneberg   (Germany)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Grade; Immunocytochemistry; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TUMOR CELL; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15044366315     PISSN: 00155659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Allred DC, Bustamante MA, Daniel CO (1990) Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg, 125: 107-113.
2. Dziegel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M (2003) Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol, 18: 401-407.
3. Elston CW, Ellis IO (1991(Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopatology, 19: 403-410.
4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connoly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med, 124: 966-978.
5. Heinaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand of mutations. Adv Cancer Res, 77: 81-137.
6. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen and progesterone receptor status. Am J Epidemiol, 151: 703-714.
7. Jensen EV, Cheng G, Palinmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci, 98: 15197-15202.
8. Keshigegian AA, Cnaan A (1996) Estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Poor clinical outcome. Arch Pathol Lab Med, 120: 970-973.
9. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 330: 1260-1266.
10. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J (2000) The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88: 804-813.
11. Remmele W, Stenger HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8: 138-140.
12. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Human Pathol, 26: 873-879.
13. Scholzen T, Gerdes J (2000) The Ki67 protein: from the known and the unknown. J Cell Physiol, 182: 311-322.
14. Slamon DJ, Clark GM, Wong SG (1987) Human breast cancer: correlation of relapse and survival with amplification of the Her-2/ neu oncogene. Science, 235: 177-182.
15. Surowiak P, Dziegiel P, Zabel M, Matkowski R, Kornafel J (2001) Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease. Fol Histochem Cytobiol, 39: 143-144.
16. Warnberg F, Nordgren H, Bergkvist L, Holmberg L (2001) Tumour markers in breast cancer correlate with grade rather than with invasiveness. Br J Cancer, 85: 869-874.
17. Zasławski R, Surowiak P, Dziegiel P, Pretnik L, Zabel M (2001) Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle. Med Sci Monit, 7: 784-789.